Analyst Price Target is $14.33
▲ +107.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for INmune Bio in the last 3 months. The average price target is $14.33, with a high forecast of $22.00 and a low forecast of $7.00. The average price target represents a 107.73% upside from the last price of $6.90.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in INmune Bio. This Buy consensus rating has held steady for over two years.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.